| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer
|
Criscitiello, C.
|
|
|
29 |
1 |
p. 162-169
|
artikel
|
| 2 |
Analyzing the impact of depth of response on survival in patients with metastatic non-small-cell lung cancer
|
Weber, S.
|
|
|
29 |
1 |
p. 282-283
|
artikel
|
| 3 |
Annals of Oncology: factors for making a real impact
|
André, F.
|
|
|
29 |
1 |
p. 28-29
|
artikel
|
| 4 |
A novel pretherapeutic gene expression-based risk score for treatment guidance in gastric cancer
|
Bauer, L.
|
|
|
29 |
1 |
p. 127-132
|
artikel
|
| 5 |
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade
|
Nuciforo, P.
|
|
|
29 |
1 |
p. 170-177
|
artikel
|
| 6 |
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results
|
Aparicio, T.
|
|
|
29 |
1 |
p. 133-138
|
artikel
|
| 7 |
Biosimilars in oncology: much ado about nothing?
|
Aapro, M.
|
|
|
29 |
1 |
p. 25-26
|
artikel
|
| 8 |
BRCA 1 and 2 mutation status: the elephant in the room during oncofertility counseling for young breast cancer patients
|
Paluch-Shimon, S.
|
|
|
29 |
1 |
p. 26-28
|
artikel
|
| 9 |
Comprehensive analysis of the clinical immuno-oncology landscape
|
Tang, J.
|
|
|
29 |
1 |
p. 84-91
|
artikel
|
| 10 |
Curcumin dietary supplements and everolimus-based cancer treatment
|
Mir, O.
|
|
|
29 |
1 |
p. 287-288
|
artikel
|
| 11 |
Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer
|
Ilié, M.
|
|
|
29 |
1 |
p. 193-199
|
artikel
|
| 12 |
Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma
|
Ghorani, E.
|
|
|
29 |
1 |
p. 271-279
|
artikel
|
| 13 |
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer
|
Siena, S.
|
|
|
29 |
1 |
p. 119-126
|
artikel
|
| 14 |
Editorial Board
|
|
|
|
29 |
1 |
p. ii
|
artikel
|
| 15 |
European Society for Medical Oncology (ESMO) position paper on supportive and palliative care
|
Jordan, K.
|
|
|
29 |
1 |
p. 36-43
|
artikel
|
| 16 |
From hepatitis C virus infection to B-cell lymphoma
|
Couronné, L.
|
|
|
29 |
1 |
p. 92-100
|
artikel
|
| 17 |
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients
|
Nabieva, N.
|
|
|
29 |
1 |
p. 186-192
|
artikel
|
| 18 |
Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness
|
Tutt, A.
|
|
|
29 |
1 |
p. 18-21
|
artikel
|
| 19 |
Instructions to authors
|
|
|
|
29 |
1 |
p. iii-x
|
artikel
|
| 20 |
Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice
|
Moorcraft, S.Y.
|
|
|
29 |
1 |
p. 230-236
|
artikel
|
| 21 |
Liquid biopsy: another tool towards tailored therapy in colorectal cancer
|
Tarazona, N.
|
|
|
29 |
1 |
p. 7-8
|
artikel
|
| 22 |
Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy
|
Rotte, A.
|
|
|
29 |
1 |
p. 71-83
|
artikel
|
| 23 |
Monitoring resistance through liquid biopsy
|
Parikh, A.R.
|
|
|
29 |
1 |
p. 8-11
|
artikel
|
| 24 |
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet
|
Armstrong, A.J.
|
|
|
29 |
1 |
p. 23-25
|
artikel
|
| 25 |
Not only tumor but also therapy heterogeneity
|
Garattini, S.
|
|
|
29 |
1 |
p. 13-18
|
artikel
|
| 26 |
Novel treatment options for refractory Germ Cell Tumours: back to the bench!
|
Kollmannsberger, C.
|
|
|
29 |
1 |
p. 21-22
|
artikel
|
| 27 |
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
|
Yoshino, T.
|
|
|
29 |
1 |
p. 44-70
|
artikel
|
| 28 |
Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer
|
Overman, M.J.
|
|
|
29 |
1 |
p. 139-144
|
artikel
|
| 29 |
Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206
|
Adra, N.
|
|
|
29 |
1 |
p. 209-214
|
artikel
|
| 30 |
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project
|
Kerr, K.M.
|
|
|
29 |
1 |
p. 200-208
|
artikel
|
| 31 |
Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?
|
Gelsomino, F.
|
|
|
29 |
1 |
p. 284-286
|
artikel
|
| 32 |
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial
|
Normanno, N.
|
|
|
29 |
1 |
p. 112-118
|
artikel
|
| 33 |
Reply to ‘The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology’ by Kirova et al.
|
Dubsky, P.
|
|
|
29 |
1 |
p. 281-282
|
artikel
|
| 34 |
Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients
|
Lambertini, M.
|
|
|
29 |
1 |
p. 237-243
|
artikel
|
| 35 |
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy
|
Blackwell, K.
|
|
|
29 |
1 |
p. 244-249
|
artikel
|
| 36 |
Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient
|
Biondani, P.
|
|
|
29 |
1 |
p. 286-287
|
artikel
|
| 37 |
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
|
Pollack, M.H.
|
|
|
29 |
1 |
p. 250-255
|
artikel
|
| 38 |
Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma
|
Kwong, Y.L.
|
|
|
29 |
1 |
p. 256-263
|
artikel
|
| 39 |
Stevens–Johnson syndrome during nivolumab treatment of NSCLC
|
Salati, M.
|
|
|
29 |
1 |
p. 283-284
|
artikel
|
| 40 |
Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients
|
Castillo, J.
|
|
|
29 |
1 |
p. 223-229
|
artikel
|
| 41 |
Table of Contents
|
|
|
|
29 |
1 |
p. xi-xiv
|
artikel
|
| 42 |
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
|
Möbus, V.
|
|
|
29 |
1 |
p. 178-185
|
artikel
|
| 43 |
Thanks to referees 2017
|
|
|
|
29 |
1 |
p. 1-6
|
artikel
|
| 44 |
The European Society for Medical Oncology (ESMO) Precision Medicine Glossary
|
Yates, L.R.
|
|
|
29 |
1 |
p. 30-35
|
artikel
|
| 45 |
The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology
|
Kirova, Y.M.
|
|
|
29 |
1 |
p. 280-281
|
artikel
|
| 46 |
The use of antidepressants in oncology: a review and practical tips for oncologists
|
Grassi, L.
|
|
|
29 |
1 |
p. 101-111
|
artikel
|
| 47 |
The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation
|
Riester, M.
|
|
|
29 |
1 |
p. 264-270
|
artikel
|
| 48 |
Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer
|
Fribbens, C.
|
|
|
29 |
1 |
p. 145-153
|
artikel
|
| 49 |
Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy
|
Jain, S.
|
|
|
29 |
1 |
p. 215-222
|
artikel
|
| 50 |
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study
|
Han, H.S.
|
|
|
29 |
1 |
p. 154-161
|
artikel
|
| 51 |
Will liquid biopsies become our fluid transition to personalized immunotherapy?
|
Wauters, E.
|
|
|
29 |
1 |
p. 11-13
|
artikel
|
Tijdschrift beschrijving